A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

Completed

Conditions studied: Anaplastic Lymphoma Kinase-positive, Carcinoma Non-small-cell Lung

In brief

The primary purpose of this study is to determine the differences in PFS for participants who have been receiving brigatinib as ALK inhibitor therapy for ALK+NSCLC compared to those participants receiving alectinib, ceritinib, lorlatinib, or other ALK inhibitors that may become available during study treatment.

Key facts

Study ID

NCT03546894

Run by

Takeda

People needed

111

Starts

2018-07-23

Expected to finish

2023-02-13

Last updated by the study team

2024-07-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Has ALK+ NSCLC.
• Has been prescribed:
• Brigatinib at any point in therapy, OR
• Any FDA approved ALK inhibitor at any point in therapy other than crizotinib. Participants who were previously on crizotinib, but are now on another ALK inhibitor are eligible for study participation.
• Has internet access.
• Is willing to answer regular e-surveys and allow for the prescriber or clinic to provide data on the status of the participant's NSCLC.

You may not qualify if…

• Has received any investigational compound within 90 days prior to consent.

Where it is running

• EmpiraMed, Inc. — Maynard, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.